Supplementary Table 1: Culture, DST and fingerprinting methodology.

\* INH: isoniazid, RIF: rifampicin, EMB: ethambutol, PZA: pyrazinamide, STR: streptomycin, ETH: ethionamide, CIP: ciprofloxacin, LEVO: levofloxacin, OFLX: ofloxacin, AMK: amikacin, KAN: kanamycin, CAP: capreomycin, PAS: para-aminosalicylic acid, CYS: cycloserine \*\* FLQ drugs tested included CIP, LEVO, OFLX, MOXI, and GATI. Spoligo: spoligotyping

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| Source | Culture | Colony purification | Drug Sensitivity Testing\* | Finger-printing |
| Stellenbosch University, South Africa | BACTEC MGIT 960 system (BD Diagnostics Systems, Sparks, MD) | No | Indirect proportion method on Middlebrook 7H11 agar slants supplemented individually with: RIF (1.0 µg/ml), INH (0.2 µg/ml), EMB (7.5 µg/ml), OFLX (2.0 µg/ml), KAN (5.0 µg/ml), STR (2.0 µg/ml), AMK (5.0 µg/ml), CAP (10 µg/ml). PZA sensitivity was tested using the MGIT 960 system (100 µg/ml). | Spoligo/ RFLP |
| Center for Disease Control, Atlanta, USA | Middlebrook 7H9 broth supplemented with 10% (vol/vol) albumin-dextrose-catalase enrichment (Difco Laboratories) and 0.05% (vol/vol) Tween 80 (Sigma-Aldrich) at 37°C until they reached an approximate optical density at 600 nm of 1.0 (corresponding to 5 x 108  CFU/ml) | No | Indirect proportion method on Middlebrook 7H10 agar plates supplemented individually with: RIF (1 µg/ml), INH (0.2, 1, and 5µg/ml), EMB (5 µg/ml), OFLX (2 µg/ml), CIP (2 µg/ml), STR (2.0 µg/ml) KAN (5 µg/ml), CAP (10 µg/ml), and AMI (4 µg/ml). PZA was tested using the BACTEC 460 (100 µg/ml), MGIT (100 µg/ml), or agar proportion (25 µg/ml) method. | Spoligo |
| Mass State Laboratory (source country Peru, Russia), Boston, USA | Radiometric BACTEC 460 TB system (Becton-Dickinson) | No | Indirect proportion method on Middlebrook 7H10 agar plates supplemented with : INH ( 0.2, 1, and 5 μg/mL), RIF (1 μg/mL), EMB (5 μg/mL), STR (2 and 10 μg/mL), KAN (5 μg/mL), CAP (10 μg/mL), ETH (5 μg/mL), CYS (30 μg/mL), PAS (1 μg/mL), AMK (6 μg/mL), LEVO (1 μg/mL), OFLX (2 μg/mL), and CIP (2 µg/mL). PZA was tested using the BACTEC (100 μg/mL). | Spoligo |
| Public Health Research Institute, Rutgers University,  Newark, NJ | Lowenstein-Jensen slant culture | No | Indirect agar proportion method on Middlebrook 7H10 agar plates containing the following drugs: RIF (1 µg/ml), INH (0.2, 1, and 5µg/ml), EMB (5 µg/ml), CIP (2 µg/ml), STR (2µg/ml), KAN (5 µg/ml), CAP (10µg/ml) | Spoligo/ RFLP |
| RVIM, Netherlands | MGIT and Middlebrook 7H10 solid | No | MGIT INH (0.2 μg/mL), RIF (1 μg/mL), RFB (2 μg/mL), EMB (5 μg/mL), STR (5 μg/mL), ETH (5 μg/mL), CYS (50 μg/mL), PRO (5 μg/mL), AMK (5 μg/mL), CLO (2 μg/mL), and CIP (2 µg/mL). PZA (50 μg/mL), CLARI (>16 μg/mL), PAS (1 μg/mL). | Spoligo/ MIRU-VNTR |
| WHO/TDR, Belgium | Dubos Agar then Lowenstein-Jensen slant culture | Yes | Indirect proportions method on two different media: On LJ for INH (0.2 μg/ml), RIF (40 μg/ml), EMB (2μg/ml),STR (4 μg/ml),PAS(0.5 μg/ml); on Middlebrook 7H11 agar for  OFLX (2μg/ml), KAN (6μg/ml), CAP (10μg/ml). |  |